News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Navidea Biopharmaceuticals Announces Fourth Quarter and Full-Year 2012 Results
March 7, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced consolidated results for the fourth quarter of 2012 and for the year ended December 31, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Cancer
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
September 22, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
BMS says goodbye to 265 New Jersey staff as reorg rolls on
September 22, 2026
·
95 min read
·
BioSpace Editorial Staff
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
·
2 min read
·
Nick Paul Taylor
C-suite
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
September 21, 2026
·
5 min read
·
Annalee Armstrong
